NCT03882060View on ClinicalTrials.gov

Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 8, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Moyamoya DiseasePediatricsCerebrovascular Disorders
Interventions
DRUG

erythropoietin

Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.

DRUG

Normal saline

Control group, no intervention.

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT03882060 - Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients | Biotech Hunter | Biotech Hunter